Indevus Sanctura Comparative Claims Not Supported By NDA, FDA Finds
This article was originally published in Pharmaceutical Approvals Monthly
Indevus’ NDA for Sanctura did not support a claim that trospium has a superior central nervous system adverse event profile to other anticholinergics, FDA review documents indicate.
You may also be interested in...
The urinary incontinence market could see the entry of two significant competitors in 2003, with recent NDA submissions for Pfizer’s darifenacin and Yamanouchi’s solifenacin (YM-905).
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011